Imatinib for COVID-19
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: University of Maryland, Baltimore
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Approved in 5 jurisdictions
Trial Summary
What is the purpose of this trial?This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
Eligibility Criteria
This trial is for hospitalized adults over 18 with a positive COVID-19 test. They must understand and sign consent, or have a representative do so if they're too unwell. Excluded are pregnant/breastfeeding women, those in other drug trials (except certain emergency use treatments), people allergic to Imatinib, and those with severe heart, liver, kidney or blood disorders.Inclusion Criteria
I am 18 or older and currently in the hospital.
Exclusion Criteria
My liver and kidney functions are within normal limits.
My blood counts are within a healthy range.
Treatment Details
The study tests the safety and effectiveness of Imatinib compared to a placebo in treating COVID-19 in hospitalized adults. It's randomized (participants are randomly assigned) and double-blind (neither participants nor researchers know who gets what treatment).
2Treatment groups
Experimental Treatment
Active Control
Group I: ImatinibExperimental Treatment1 Intervention
Imatinib oral 400 mg daily for 14 days.
Group II: PlaceboActive Control1 Intervention
Placebo oral for 14 days
Imatinib is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:
🇪🇺 Approved in European Union as Gleevec for:
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
🇺🇸 Approved in United States as Gleevec for:
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
🇨🇦 Approved in Canada as Glivec for:
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
🇯🇵 Approved in Japan as Glivec for:
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
🇨🇭 Approved in Switzerland as Gleevec for:
- Chronic myeloid leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans
- Systemic mastocytosis
- Hypereosinophilic syndrome
Find a clinic near you
Research locations nearbySelect from list below to view details:
University of Maryland Medical CenterBaltimore, MD
Loading ...
Who is running the clinical trial?
University of Maryland, BaltimoreLead Sponsor